Kevin M. Koch

9.9k total citations · 1 hit paper
194 papers, 7.4k citations indexed

About

Kevin M. Koch is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Kevin M. Koch has authored 194 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 59 papers in Radiology, Nuclear Medicine and Imaging and 45 papers in Molecular Biology. Recurrent topics in Kevin M. Koch's work include HER2/EGFR in Cancer Research (36 papers), Advanced MRI Techniques and Applications (35 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Kevin M. Koch is often cited by papers focused on HER2/EGFR in Cancer Research (36 papers), Advanced MRI Techniques and Applications (35 papers) and Chronic Lymphocytic Leukemia Research (20 papers). Kevin M. Koch collaborates with scholars based in United States, United Kingdom and Spain. Kevin M. Koch's co-authors include Brian A. Hargreaves, Garry E. Gold, Kevin F. King, Kim Butts Pauly, Deborah A. Smith, Pauline W. Worters, Hollis G. Potter, Douglas L. Rothman, Andrew G. Stead and Robin A. de Graaf and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Chemical Physics and Journal of Clinical Oncology.

In The Last Decade

Kevin M. Koch

185 papers receiving 7.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 503 citations Howard A. Burris, Beth Overmoyer et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin M. Koch United States	45	2.4k	2.1k	1.8k	981	940	194	7.4k
Michael Schäfers Germany	56	1.8k 0.7×	4.0k 1.9×	2.9k 1.6×	1.3k 1.4×	2.4k 2.5×	373	11.5k
Nagichettiar Satyamurthy United States	52	1.3k 0.6×	3.9k 1.8×	3.1k 1.7×	530 0.5×	804 0.9×	179	11.0k
Otmar Schober Germany	50	1.1k 0.4×	3.4k 1.6×	1.1k 0.6×	1.5k 1.5×	1.8k 1.9×	353	9.2k
François Bénard Canada	52	1.8k 0.7×	4.7k 2.2×	1.3k 0.7×	946 1.0×	2.6k 2.7×	376	9.3k
Susan J. Knox United States	46	2.3k 0.9×	2.3k 1.1×	1.9k 1.1×	339 0.3×	1.3k 1.4×	171	7.2k
Simon P. Robinson United Kingdom	49	1.2k 0.5×	3.7k 1.7×	2.0k 1.1×	529 0.5×	859 0.9×	243	8.1k
Michael Höckel Germany	48	2.6k 1.1×	2.0k 1.0×	4.0k 2.2×	1.7k 1.7×	1.7k 1.8×	189	12.8k
Paul Okunieff United States	50	2.1k 0.9×	3.4k 1.6×	2.4k 1.3×	1.6k 1.7×	3.7k 4.0×	233	11.3k
Yicheng Ni Belgium	44	1.2k 0.5×	2.3k 1.1×	1.4k 0.7×	918 0.9×	1.4k 1.4×	279	7.1k
Michael R. Horsman Denmark	55	1.7k 0.7×	2.8k 1.3×	3.5k 1.9×	483 0.5×	2.1k 2.2×	252	10.2k

Countries citing papers authored by Kevin M. Koch

Since Specialization

Citations

This map shows the geographic impact of Kevin M. Koch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin M. Koch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin M. Koch more than expected).

Fields of papers citing papers by Kevin M. Koch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin M. Koch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin M. Koch. The network helps show where Kevin M. Koch may publish in the future.

Co-authorship network of co-authors of Kevin M. Koch

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin M. Koch. A scholar is included among the top collaborators of Kevin M. Koch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin M. Koch. Kevin M. Koch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koch, Kevin M., Andrew S. Nencka, Shekar N. Kurpad, & Matthew D. Budde. (2024). Diffusion Weighted Magnetic Resonance Imaging of Spinal Cord Injuries After Instrumented Fusion Stabilization. Journal of Neurotrauma. 41(17-18). 2125–2132.

Argentieri, Erin C., et al.. (2022). MAVRIC based T2 mapping assessment of infrapatellar fat pad scarring in patients with total knee arthroplasty. Journal of Orthopaedic Research®. 41(6). 1299–1309. 2 indexed citations

Brett, Benjamin L., Yu‐Chien Wu, Sourajit M. Mustafi, et al.. (2020). The Association Between Persistent White-Matter Abnormalities and Repeat Injury After Sport-Related Concussion. PMC.

Wang, Yang, Andrew S. Nencka, Timothy B. Meier, et al.. (2018). Cerebral blood flow in acute concussion: preliminary ASL findings from the NCAA-DoD CARE consortium. Brain Imaging and Behavior. 13(5). 1375–1385. 43 indexed citations

Koff, Matthew F., Alissa J. Burge, Kevin M. Koch, & Hollis G. Potter. (2017). Imaging near orthopedic hardware. Journal of Magnetic Resonance Imaging. 46(1). 24–39. 32 indexed citations

Chien, A. Jo, Pamela N. Münster, Michelle Melisko, et al.. (2014). Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer. Journal of Clinical Oncology. 32(14). 1472–1479. 30 indexed citations

Fumoleau, P., Kevin M. Koch, Étienne Brain, et al.. (2014). A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). The Breast. 23(5). 663–669. 10 indexed citations

Koch, Kevin M., Geraldine Ferron‐Brady, Leanne Cartee, et al.. (2014). Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. Clinical Pharmacology in Drug Development. 4(3). 203–209. 5 indexed citations

Crown, John, Megan Kennedy, Patricia Tresca, et al.. (2013). Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of Oncology. 24(8). 2005–2011. 12 indexed citations

10.

Devriese, Lot A., Kevin M. Koch, Marja Mergui‐Roelvink, et al.. (2013). Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Investigational New Drugs. 32(3). 481–488. 41 indexed citations

11.

Worters, Pauline W., Kyunghyun Sung, Kathryn J. Stevens, Kevin M. Koch, & Brian A. Hargreaves. (2012). Compressed‐Sensing multispectral imaging of the postoperative spine. Journal of Magnetic Resonance Imaging. 37(1). 243–248. 59 indexed citations

12.

Burris, Howard A., Charles W. Taylor, Suzanne F. Jones, et al.. (2009). A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clinical Cancer Research. 15(21). 6702–6708. 83 indexed citations

13.

Molina, Julian R., Scott H. Kaufmann, Joel M. Reid, et al.. (2008). Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data. Clinical Cancer Research. 14(23). 7900–7908. 41 indexed citations

14.

Storniolo, Anna Maria, Mark D. Pegram, Beth Overmoyer, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology. 26(20). 3317–3323. 89 indexed citations

15.

Yeh, Tammie C., Vivienne Marsh, Bryan A. Bernat, et al.. (2007). Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. Clinical Cancer Research. 13(5). 1576–1583. 442 indexed citations

16.

Woessner, Richard, Shelley Allen, Qian Zhao, et al.. (2007). ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Cancer Research. 67. 1433–1433. 9 indexed citations

17.

Midgley, Rachel, Rachel Kerr, Keith T. Flaherty, et al.. (2007). A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology. 18(12). 2025–2029. 43 indexed citations

18.

Bence, Aimee K., Michael Doukas, George A. Davis, et al.. (2004). Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Investigational New Drugs. 23(1). 39–49. 98 indexed citations

19.

Reiter, Lawrence A., Kevin M. Koch, Anthony D. Piscopio, et al.. (1998). trans-3-Benzyl-4-hydroxy-7-chromanylbenzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor. Bioorganic & Medicinal Chemistry Letters. 8(14). 1781–1786. 11 indexed citations

20.

Krause, Hans‐Joachim, et al.. (1982). [Sensation and sensibility disorders in amyotrophic lateral sclerosis].. PubMed. 34(2). 107–10. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact